Those with a finger on the pulse of the US Drug Supply Chain Security Act (DSCSA) will have heard from all rooftops by now that FDA has granted all pharmaceutical Trading Partners a 12-month Stabilization
Continue …Take heed of the underscore! … or why the DSCSA Stabilization Period is not for fun
Outlining the work of the Open Credentialing Initiative in establishing digital proof of identity, licensure status, and authorship using digital wallets and verifiable credentials … Continue …Closing a Key Gap in DSCSA Compliance
Despite potential short-cuts, drug development is a lengthy and risky process that culminates in marketing approval. However, just because a drug achieves regulatory approval, does not mean that it will be instantly available to those
I feel that there is considerable confusion about drug prices amongst industry outsiders. Until I started looking into the topic, I had no idea how complex it was.
In 2019, I graduated with Distinction from the roller-coaster that was my one-year full-time MSc in Finance and Investment Management at the University of Aberdeen, Scotland.
Click to read >>>
Considering the importance of antibiotics for our healthcare, the issue of a dwindling development pipeline must be addressed. This article outlines various economic suggestions.
Click to read >>>
Planning and financing healthcare is a challenging task for individuals, private insurance providers and governments. Public and private insurances must cater for a vast number of people ideally equally across all income classes. Indeed, increased